Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer
VANCOUVER, British Columbia , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Jeffrey Hackman as Executive
View HTML
Toggle Summary Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D
VANCOUVER, British Columbia , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Murray Stewart , M.D.
View HTML
Toggle Summary Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , Sept. 24, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH
View HTML
Toggle Summary Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Sept. 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of two separate
View HTML
Toggle Summary Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
VANCOUVER, British Columbia , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Suzanne Bruhn , Ph.D.
View HTML
Toggle Summary Novelion Therapeutics Reports Second Quarter 2017 Financial Results
MYALEPT® Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time Adjustments Global Expansion Plans for Metreleptin Opportunity Underway Company Updates Guidance for FY 2017 Total Net Revenues Conference call to be held today at 8:30 a.m. ET VANCOUVER , Aug.
View HTML
Toggle Summary Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors
VANCOUVER, British Columbia , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark DiPaolo to its board of directors,
View HTML
Toggle Summary Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
Conference call and Webcast Scheduled for 8:30am ET
View HTML
Toggle Summary Novelion Therapeutics Added to the Russell 3000® & Russell Microcap® Indexes
VANCOUVER, British Columbia , June 26, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that it has been added to the Russell 3000® and Russell
View HTML
Toggle Summary Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , June 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by researchers
View HTML